Last reviewed 2026-04-23 · How we verify

HGP1705

HGP1705 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.

HGP1705 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes. Used for Type 2 diabetes mellitus.

At a glance

Mechanism of action

HGP1705 binds to and activates the glucagon-like peptide-1 (GLP-1) receptor on pancreatic beta cells, stimulating glucose-dependent insulin secretion. The drug also suppresses glucagon secretion and slows gastric emptying, collectively reducing postprandial and fasting blood glucose levels. Its extended half-life allows for less frequent dosing compared to shorter-acting GLP-1 agonists.

Approved indications

• Type 2 diabetes mellitus

Common side effects

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Hypoglycemia

Key clinical trials

• Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of HIP1802 to HGP1705 in Healthy Volunteers (PHASE1)
• Efficacy and Safety of HIP1601 Capsule (PHASE3)
• Safety, Pharmacokinetics and Pharmacodynamics of the Two Esomeprazole Formulations (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• HGP1705 CI brief — competitive landscape report
• HGP1705 updates RSS · CI watch RSS
• Hanmi Pharmaceutical Company Limited portfolio CI